25 related articles for article (PubMed ID: 2465929)
1. Metastatic phenotype of human prostate tumor cells in athymic nude mice: alteration by exposure to ethyl methanesulfonate and "reversion" by 5-azacytidine.
Ware JL; Lieberman AP; Webb KS
Cancer Immunol Immunother; 1986; 21(1):58-62. PubMed ID: 2417701
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing phenotypic diversity of human prostate carcinoma cells metastasizing in athymic nude mice.
Ware JL; Lieberman AP; Webb KS; Vollmer RT
Exp Cell Biol; 1985; 53(3):163-9. PubMed ID: 4007233
[TBL] [Abstract][Full Text] [Related]
3. Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine.
Frost P; Liteplo RG; Donaghue TP; Kerbel RS
J Exp Med; 1984 May; 159(5):1491-501. PubMed ID: 6201588
[TBL] [Abstract][Full Text] [Related]
4. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.
Pettaway CA; Pathak S; Greene G; Ramirez E; Wilson MR; Killion JJ; Fidler IJ
Clin Cancer Res; 1996 Sep; 2(9):1627-36. PubMed ID: 9816342
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma.
Carlow DA; Kerbel RS; Feltis JT; Elliott BE
J Natl Cancer Inst; 1985 Aug; 75(2):291-301. PubMed ID: 2410653
[TBL] [Abstract][Full Text] [Related]
6. Clonal variation in the impact of ethyl methanesulfonate and 5-azacytidine on the metastatic phenotype of human prostatic tumor cells in athymic nude mice.
Ware JL
Exp Cell Biol; 1988; 56(5):270-6. PubMed ID: 2465929
[TBL] [Abstract][Full Text] [Related]
7. Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment.
Kerbel RS; Frost P; Liteplo R; Carlow DA; Elliott BE
J Cell Physiol Suppl; 1984; 3():87-97. PubMed ID: 6205005
[TBL] [Abstract][Full Text] [Related]
8. Experimental systems for analysis of the malignant phenotype.
Poste G
Cancer Metastasis Rev; 1982; 1(2):141-99. PubMed ID: 6764376
[TBL] [Abstract][Full Text] [Related]
9. [In vitro and in vivo models developed from human prostatic cancer].
Bladou F; Gleave ME; Penault-Llorca F; Serment G; Lange PH; Vessella RL
Prog Urol; 1997 Jun; 7(3):384-96. PubMed ID: 9273065
[TBL] [Abstract][Full Text] [Related]
10. Modification of the metastatic potential of tumor cells by drugs.
Takenaga K
Cancer Metastasis Rev; 1986; 5(2):67-75. PubMed ID: 2435428
[TBL] [Abstract][Full Text] [Related]
11. Metastatic diversity in human prostatic carcinoma: implications of growth factors and growth factor receptors for the metastatic phenotype.
Ware JL; Maygarden SJ
Pathol Immunopathol Res; 1989; 8(5-6):231-49. PubMed ID: 2561207
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
